Prime MedicinePRME
PRME
About: Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
Employees: 214
0
Funds holding %
of 7,312 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
17% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 35
0% more funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 1 (+0) [Q1 2025]
3.03% less ownership
Funds ownership: 49.05% [Q4 2024] → 46.02% (-3.03%) [Q1 2025]
5% less funds holding
Funds holding: 130 [Q4 2024] → 123 (-7) [Q1 2025]
22% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 27
36% less capital invested
Capital invested by funds: $188M [Q4 2024] → $120M (-$67.6M) [Q1 2025]
49% less call options, than puts
Call options by funds: $120K | Put options by funds: $237K
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$1.50
66%
downside
Avg. target
$6.50
49%
upside
High target
$12
176%
upside
3 analyst ratings
2 positive
67%
1 neutral
33%
0 negative
0%
Citigroup Samantha Semenkow | 66%downside $1.50 | Neutral Downgraded | 27 May 2025 |
JMP Securities Silvan Tuerkcan | 38%upside $6 | Market Outperform Maintained | 20 May 2025 |
Chardan Capital Geulah Livshits | 176%upside $12 | Buy Maintained | 19 May 2025 |
Financial journalist opinion
Positive
Seeking Alpha
4 days ago
Prime Medicine: Pressing Forward With Lead Liver Targeting Indications
Prime Medicine, Inc. achieved strong early data in CGD with PM359, surpassing efficacy thresholds, but is pivoting to larger in-vivo gene editing liver disease targeting opportunities. PRME is prioritizing in-vivo gene editing therapy programs targeting Wilson's Disease and Alpha-1 Antitrypsin Deficiency, with IND filings expected in H1 and mid-2026, respectively. These new programs use in-vivo LNP delivery, target larger markets, and could provide substantially better advantages for PRME over ex-vivo gene editing.
Neutral
GlobeNewsWire
1 month ago
Prime Medicine to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that company management will participate in the following upcoming conferences: Jefferies Global Healthcare Conference: Fireside chat on Thursday, June 5, 2025, at 10:30 a.m.
Neutral
GlobeNewsWire
1 month ago
Prime Medicine Announces Strategic Restructuring to Focus on Opportunities in Large Genetic Liver Diseases, Cystic Fibrosis, and Partnered Programs Alongside CEO Leadership Transition
-- Initial positive data from Phase 1/2 clinical trial of PM359 in CGD provide clinical proof-of-concept for Prime Editing as a transformative gene editing technology -- -- On-track to file IND and/or CTA for Wilson's Disease and AATD programs in 1H 2026 and mid-2026, respectively; initial clinical data for both expected in 2027 --
Neutral
GlobeNewsWire
1 month ago
Prime Medicine Announces Breakthrough Clinical Data Showing Rapid Restoration of DHR Positivity After Single Infusion of PM359, an Investigational Prime Editor for Chronic Granulomatous Disease
-- First ever clinical data supporting safety and efficacy of Prime Editing in humans -- -- Initial data from first patient dosed in Phase 1/2 trial finds single dose of PM359 led to 58% DHR positivity by Day 15 and 66% by Day 30, well above levels believed to be potentially curative --
Negative
Zacks Investment Research
2 months ago
Prime Medicine, Inc. (PRME) Reports Q1 Loss, Misses Revenue Estimates
Prime Medicine, Inc. (PRME) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.44 per share a year ago.
Neutral
GlobeNewsWire
2 months ago
Prime Medicine Reports First Quarter 2025 Financial Results and Provides Business Updates
-- Initial data from Phase 1/2 trial of PM359 for p47 phox CGD expected in 2025 -- -- IND and/or CTA for PM577 for Wilson's Disease on-track for 1H 2026 -- -- Unveiled potentially best-in-class program for AATD; IND and/or CTA filing targeted for mid-2026 -- CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today reported financial results for the quarter ended March 31, 2025 and provided a business update.
Positive
The Motley Fool
3 months ago
Why Prime Medicine Stock Was Climbing Higher This Week
News of a fresh investigational program was putting some zip into the shares of gene-editing company Prime Medicine (PRME) across recent trading sessions. According to data compiled by S&P Global Market Intelligence, in reaction, bullish investors were propelling the company's stock over 12% higher week to date as of early Thursday evening.
Positive
The Motley Fool
3 months ago
Why Prime Medicine Stock Is Soaring Today
Shares of Prime Medicine (PRME 12.50%) are surging on Thursday. The gene-editing company's stock gained 10.5% as of 2 p.m.
Neutral
GlobeNewsWire
3 months ago
Prime Medicine Unveils Program for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
-- Prime Editing has potential to be best-in-class approach for AATD -- -- Previously undisclosed program now emerging from within liver platform; leverages proprietary, universal liver LNP --
Neutral
GlobeNewsWire
4 months ago
Prime Medicine Reports Full Year 2024 Financial Results and Provides Business Updates
-- On track to report initial data from Phase 1/2 clinical trial of PM359 for p47 phox CGD in 2025 -- -- IND-enabling studies ongoing for PM577 for Wilson's Disease; expect to file IND and/or CTA in 1H 2026 -- -- Additional high-value programs advancing through preclinical development -- CAMBRIDGE, Mass., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today reported financial results for the full year ended December 31, 2024 and provided a business update.
Charts implemented using Lightweight Charts™